FDA Approves Sub-Q Tx for LDL Control – Leqvio
Last week the FDA approved Leqvio, from Novartis Pharmaceuticals. Leqvio is a first-in-class, RNAi sub-Q therapy indicated as an adjunct to diet and maximally tolerated
December 30, 2021
Last week the FDA approved Leqvio, from Novartis Pharmaceuticals. Leqvio is a first-in-class, RNAi sub-Q therapy indicated as an adjunct to diet and maximally tolerated
The public relations battle surrounding White Bagging is heating up. Who’s on each side? Depends on who you ask….! On one side, hospitals are claiming that
The FDA has approved a new INFUSED biologic, Vyvgart (efgartigimod alfa-fcab, Argenx), for treatment of generalized Myasthenia Gravis (gMG) in adults who are acetylcholine receptor
The FDA approved a new, subcutaneous biologic last week, Tezspire (tezepelumab-ekko) from Amgen and AstraZeneca, an add-on maintenance treatment for adult and pediatric patients (12+)
Specialty pharmacies should be well into forecasting for the upcoming year. Cash in fuels cash out….. and you know that more of the former is critical
The press release below raised eyebrows. At first, we thought that Omnicell had acquired ReCept Specialty Pharmacy. ReCept is a four decades long running specialty provider and
Just before Thanksgiving the FDA approved a new ORAL therapy, Livtencity (maribavir) from Takeda Pharmaceuticals, with an indication for the treatment of adults and pediatric
Last week the FDA approved a new infused therapy, Fyarro (sirolimus protein-bound particles for injectable suspension / albumin-bound) from Aadi Bioscience, for the treatment of
I’ve editorialized about the encroachment of health system owned specialty pharmacies (HOSPs) into the independent SP space since 2013. Each prescription that is directed ‘in-system’
Last week the FDA approved a new subcutaneous therapy, Voxzogo (vosoritide) from BioMarin, to improve growth in children five years of age and older with